Century-Old TB Vaccine Shows Promise Against Type 1 Diabetes, MGH Research Finds

Century-Old TB Vaccine Shows Promise Against Type 1 Diabetes, MGH Research Finds

A new study finds that an inexpensive vaccine used globally to prevent tuberculosis may help treat Type 1 diabetes — if given time to kick in. Six years after publishing phase 1 clinical trial results, which did not show clinical benefit, Massachusetts General Hospital researchers report promising follow-up data, collected over eight years after the initial trial. […]

The Trends and Opportunities in the International Multicenter Clinical Trials in Russia, ARS PharmRussia Comments

The Trends and Opportunities in the International Multicenter Clinical Trials in Russia, ARS PharmRussia Comments

     (Logo: https://mma.prnewswire.com/media/628029/ARS_PharmRussia_Logo.jpg ) Analysis of situation with the international clinical research projects in Russia: Annually, the Russian Ministry of Health (MoH) approves approximately 300 international clinical studies financed by the Sponsors from abroad. In 2017, about 100 overseas pharmaceutical and biotechnology companies initiated their multinational clinical trials in Russia to enroll 27,000 local patients in […]

Clinical Data Management Leaders Reveal Underlying Challenges Impacting Trial Timelines

Clinical Data Management Leaders Reveal Underlying Challenges Impacting Trial Timelines

BOSTON & PLEASANTON, Calif.–(BUSINESS WIRE)–Jun 21, 2018–At the upcoming DIA 2018 Annual Meeting, Tufts Center for the Study of Drug Development (CSDD) will preview its study findings on the root causes for delays and inefficiencies impacting trial timelines. As a follow-up to the , sponsored by Veeva Systems (NYSE:VEEV), Tufts CSDD spoke with more than […]

Sponsors to benefit from simplified home-based clinical trials: LabConnect CEO

Sponsors to benefit from simplified home-based clinical trials: LabConnect CEO

LabConnect, LLC​ provides central laboratory and support services for biopharmaceutical, medical device and, contract research organizations (CROs). The company has worked with Symphony Clinical Research, an in-home clinical service provider, on 17 studies over 12 years. This week, the companies announced a new strategic collaboration that will focus on integrating their services to support the […]

Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal …

Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal …

“The initiation of the VOYAGER Phase 3 trial represents an important milestone for Blueprint Medicines, as we advance efforts to achieve registration of avapritinib in a broad GIST population,” said Andy Boral, M.D., Ph.D., Chief Medical Officer of Blueprint Medicines. “With compelling Phase 1 clinical data showing objective responses and prolonged progression free survival in […]

Blueprint Medicines (BPMC) Commences VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced …

Blueprint Medicines (BPMC) Commences VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced …

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced it has dosed the first patient in the VOYAGER Phase 3 clinical trial, which is […]

Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients

Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients

AUSTIN, Texas and RALEIGH, N.C., June 21, 2018 (GLOBE NEWSWIRE) — Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research, the only platform that brings clinical research direct to clinical health care, are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients. Both companies […]

Enrollment of first patient in Phase II clinical trial for Gaucher disease

Enrollment of first patient in Phase II clinical trial for Gaucher disease

Orphazyme A/SCompany announcement                                                                                                                   No. 08/2018                                                                                                                                        Company Registration No. 32266355                                                                                                                                                                                              Copenhagen, June 21, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the first patient has received the first dose in a Phase II clinical trial for Gaucher disease. Anders Hinsby, Chief Executive Officer, said: “With […]

On “The Longest Day,” A Look at Alzheimer's Clinical Trials

On “The Longest Day,” A Look at Alzheimer's Clinical Trials

June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease. As most everyone knows, Alzheimer’s is a common form of dementia. In the U.S., it affects about 5.7 million people. Without any cure, it is estimated that by 2050, 14 million Americans […]

Moleculin Receives Approval for Leukemia Clinical Trial

Moleculin Receives Approval for Leukemia Clinical Trial

HOUSTON, June 20, 2018 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq:MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has received […]

1 2 3 69